{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:32:59Z","timestamp":1769740379549,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T00:00:00Z","timestamp":1452643200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3B1081"],"award-info":[{"award-number":["CMRPG3B1081"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3C1261"],"award-info":[{"award-number":["CMRPG3C1261"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s11060-016-2056-6","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T17:33:03Z","timestamp":1452706383000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The effects of antiepileptic drugs on the growth of glioblastoma cell lines"],"prefix":"10.1007","volume":"127","author":[{"given":"Ching-Yi","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"She-Hung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Ping","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Tseng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"key":"2056_CR1","unstructured":"CBTRUS (2011) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004\u20132007. Source: Central Brain Tumor Registry of the United States, Hinsdale www.cbtrus.org . Accessed 13 Aug 2012"},{"issue":"2","key":"2056_CR2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"LM DeAngelis","year":"2001","unstructured":"DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114\u2013123","journal-title":"N Engl J Med"},{"key":"2056_CR3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ncl.2007.07.002","volume":"25","author":"JL Fisher","year":"2007","unstructured":"Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25:867\u2013890","journal-title":"Neurol Clin"},{"key":"2056_CR4","volume-title":"Merritt\u2019s neurology","year":"2010","unstructured":"Rowland LP, Pedley TA (eds) (2010) Merritt\u2019s neurology, 12th edn. Lippincott, Williams, & Wilkins, Philadelphia","edition":"12"},{"key":"2056_CR5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/JNN.0b013e3181c1fd83","volume":"1","author":"KC Smith","year":"2010","unstructured":"Smith KC (2010) The management of seizures in brain tumor patients. J Neurosci Nurs 1:28\u201337","journal-title":"J Neurosci Nurs"},{"key":"2056_CR6","volume-title":"Harrison\u2019s manual of oncology","year":"2008","unstructured":"Chabner BC (ed) (2008) Harrison\u2019s manual of oncology, 1st edn. McGraw-Hill Companies Inc., New York","edition":"1"},{"key":"2056_CR7","first-page":"114","volume":"169","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain MC, Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 169:114\u2013120","journal-title":"West J Med"},{"key":"2056_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.seminoncol.2004.07.005","volume":"31","author":"SA Grossman","year":"2004","unstructured":"Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635\u2013644","journal-title":"Semin Oncol"},{"key":"2056_CR9","volume-title":"Harrison\u2019s principles of internal medicine","year":"2012","unstructured":"Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds) (2012) Harrison\u2019s principles of internal medicine, 18th edn. McGraw-Hill Companies Inc., New York","edition":"18"},{"key":"2056_CR10","unstructured":"National Comprehensive Cancer Network (2011) Central nervous system cancers. NCCN clinical practice guidelines in oncology version 2"},{"key":"2056_CR11","volume-title":"Samuels\u2019s manual of neurologic therapeutics","year":"2010","unstructured":"Samuels MA, Ropper AH (eds) (2010) Samuels\u2019s manual of neurologic therapeutics, 8th edn. Lippincott, Williams, & Wilkins, Philadelphia","edition":"8"},{"issue":"Suppl 5","key":"2056_CR12","doi-asserted-by":"crossref","first-page":"v190","DOI":"10.1093\/annonc\/mdq187","volume":"21","author":"R Stupp","year":"2010","unstructured":"Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis Treatment and Follow-up. Ann Oncol 21(Suppl 5):v190\u2013v193","journal-title":"Ann Oncol"},{"key":"2056_CR13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492\u2013507","journal-title":"N Engl J Med"},{"key":"2056_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-006-9193-2","volume":"80","author":"PY Wen","year":"2006","unstructured":"Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L (2006) Medical management of patients with brain tumors. J Neurooncol 80:313\u2013332","journal-title":"J Neurooncol"},{"key":"2056_CR15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-011-1569-0","volume":"67","author":"O Kargiotis","year":"2001","unstructured":"Kargiotis O, Markoula S, Kyritsis AP (2001) Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67:489\u2013501","journal-title":"Cancer Chemother Pharmacol"},{"key":"2056_CR16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","volume":"6","author":"MSM Breemen Van","year":"2007","unstructured":"Van Breemen MSM, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421\u2013430","journal-title":"Lancet Neurol"},{"key":"2056_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.seminoncol.2006.03.009","volume":"33","author":"MR Sperling","year":"2006","unstructured":"Sperling MR, Ko J (2006) Seizures and brain tumors. Semin Oncol 33:333\u2013341","journal-title":"Semin Oncol"},{"issue":"5","key":"2056_CR18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","volume":"22","author":"RA Blaheta","year":"2002","unstructured":"Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22(5):492\u2013511","journal-title":"Med Res Rev"},{"key":"2056_CR19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ncl.2007.07.015","volume":"25","author":"J Drappatz","year":"2007","unstructured":"Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25:1035\u20131071","journal-title":"Neurol Clin"},{"issue":"Suppl 4","key":"2056_CR20","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.67.12_suppl_4.S14","volume":"67","author":"R Michelucci","year":"2006","unstructured":"Michelucci R (2006) Optimizing therapy of seizures in neurosurgery. Neurology 67(Suppl 4):S14\u2013S18","journal-title":"Neurology"},{"key":"2056_CR21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11060-009-9796-5","volume":"93","author":"A Rosati","year":"2009","unstructured":"Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A et al (2009) Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 93:395\u2013400","journal-title":"J Neurooncol"},{"key":"2056_CR22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/WCO.0b013e32833e996c","volume":"23","author":"AO Rossetti","year":"2010","unstructured":"Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients. Curr Opin Neurol 23:603\u2013609","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"2056_CR23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1046\/j.1528-1157.2003.05203.x","volume":"44","author":"B Schaller","year":"2003","unstructured":"Schaller B, Ruegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 44(9):1223\u20131232","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"2056_CR24","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/WNL.67.12_suppl_4.S10","volume":"67","author":"CJ Vecht","year":"2006","unstructured":"Vecht CJ, Van Breemen M (2006) Optimizing therapy of seizures in patients with brain tumors. Neurology 67(Suppl 4):S10\u2013S13","journal-title":"Neurology"},{"issue":"3","key":"2056_CR25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","volume":"26","author":"HC Tsai","year":"2012","unstructured":"Tsai HC, Wei KC, Tsai CN, Huang YC, Chen PY, Chen SM et al (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 26(3):347\u2013354","journal-title":"Br J Neurosurg"},{"issue":"5","key":"2056_CR26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/09553002.2011.556173","volume":"87","author":"M Salvo De","year":"2011","unstructured":"De Salvo M, Maresca G, D\u2019Angano I, Marchese R, Stigliano A, Gagliassi R et al (2011) Temozolomide induced c-Myc-mediated apoptosis via akt signaling in mgmt expressing glioblastoma cells. Int J Radiat Biol 87(5):518\u2013533","journal-title":"Int J Radiat Biol"},{"key":"2056_CR27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.cdd.4401359","volume":"11","author":"T Kanzawa","year":"2004","unstructured":"Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448\u2013457","journal-title":"Cell Death Differ"},{"issue":"52","key":"2056_CR28","doi-asserted-by":"crossref","first-page":"40461","DOI":"10.1074\/jbc.M110.164046","volume":"285","author":"WB Zhang","year":"2010","unstructured":"Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ et al (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285(52):40461\u201340471","journal-title":"J Biol Chem"},{"key":"2056_CR29","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/0008-5472.CAN-10-3213","volume":"71","author":"EM Goellner","year":"2011","unstructured":"Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF et al (2011) Overcoming temozolomide resistance in glioblastoma via dual inhibition of nad+ biosynthesis and base excision repair. Cancer Res 71:2308\u20132317","journal-title":"Cancer Res"},{"key":"2056_CR30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/07357900701788080","volume":"26","author":"A Das","year":"2008","unstructured":"Das A, Banik NL, Ray SK (2008) Modulatory effect of acetazolomide and dexamethasone on temozolomide mediated apoptosis in human glioblastoma T98G and U87MG cells. Cancer Invest 26:352\u2013358","journal-title":"Cancer Invest"},{"key":"2056_CR31","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-10-3203","volume":"17","author":"MA Moroz","year":"2011","unstructured":"Moroz MA, Huang R, Kochetkov T, Shi W, Thaler H, de Stanchina E et al (2011) Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res 17:3282\u20133292","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2056_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps040438","volume":"4","author":"PL Toutain","year":"2002","unstructured":"Toutain PL (2002) Pharmacokinetic\/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS PharmSci 4(4):1\u201329","journal-title":"AAPS PharmSci"},{"issue":"3","key":"2056_CR33","doi-asserted-by":"crossref","first-page":"E532","DOI":"10.1208\/aapsj070354","volume":"7","author":"ECM Lange de","year":"2005","unstructured":"de Lange ECM, Ravenstijn PGM, Groenendaal D, van Steeg TJ (2005) Towards the prediction of cns drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7(3):E532\u2013E542","journal-title":"AAPS J"},{"issue":"11","key":"2056_CR34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clin Pharmacokinet 45(11):1061\u20131075","journal-title":"Clin Pharmacokinet"},{"key":"2056_CR35","unstructured":"Micromedex\u00ae Healthcare Series [Internet database] Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically"},{"key":"2056_CR36","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"LL Brunton","year":"2011","unstructured":"Brunton LL, Chabner BA, Knollmann BC (2011) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Companies Inc, New York","edition":"12"},{"key":"2056_CR37","volume-title":"Pharmacotherapy: a pathophysiologic approach","year":"2011","unstructured":"DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds) (2011) Pharmacotherapy: a pathophysiologic approach, 8th edn. McGraw-Hill Companies Inc., New York","edition":"8"},{"key":"2056_CR38","volume-title":"Basic & clinical pharmacology","year":"2012","unstructured":"Katzung BG, Masters SB, Trevor AJ (eds) (2012) Basic & clinical pharmacology, 12th edn. McGraw-Hill Companies Inc., New York","edition":"12"},{"key":"2056_CR39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"CM Das","year":"2007","unstructured":"Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE et al (2007) Valproic acid induces p21 and topoisomerase-II (\u03b1\/\u03b2) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159\u2013170","journal-title":"J Neurooncol"},{"issue":"4","key":"2056_CR40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/neuonc\/nop005","volume":"12","author":"J Fu","year":"2010","unstructured":"Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-Oncology 12(4):328\u2013340","journal-title":"Neuro-Oncology"},{"issue":"5","key":"2056_CR41","first-page":"104","volume":"39","author":"S Wagner","year":"2009","unstructured":"Wagner S, van Gool S, Hau P, Pietsch T, Peters O, Wolff J (2009) Valproic acid as a potent substance for increasing efficacy of topoisomerase i inhibitors. Turk J Cancer 39(5):104\u2013109","journal-title":"Turk J Cancer"},{"key":"2056_CR42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7314\/APJCP.2014.15.1.199","volume":"15","author":"FZ Sharkawi El","year":"2014","unstructured":"El Sharkawi FZ, El Shemy HA, Khaled HM (2014) Possible anticancer activity of rosuvastatine, doxazosin, repaglinide, and oxcarbazepin. Asian Pac J Cancer Prev 15:199\u2013203","journal-title":"Asian Pac J Cancer Prev"},{"key":"2056_CR43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.yebeh.2004.07.004","volume":"5","author":"D Schmidt","year":"2004","unstructured":"Schmidt D, Elger CE (2004) What in the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5:627\u2013635","journal-title":"Epilepsy Behav"},{"issue":"4","key":"2056_CR44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"RA Blaheta","year":"2005","unstructured":"Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights in the mechanism and clinical studies. Med Res Rev 25(4):383\u2013397","journal-title":"Med Res Rev"},{"issue":"3","key":"2056_CR45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/tlo.08136","volume":"1","author":"S Sharma","year":"2008","unstructured":"Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N (2008) A phase II clinical trail of oral valroic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 1(3):141\u2013147","journal-title":"Transl Oncol"},{"key":"2056_CR46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E (2007) Valproic Acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177\u2013182","journal-title":"Br J Cancer"},{"issue":"3","key":"2056_CR47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tranon.2014.03.001","volume":"7","author":"J Bauman","year":"2014","unstructured":"Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Fekrazad MH, Lee FC, Rabinowitz I, Ravindranathan M, Jones DV Jr (2014) A phase I protocol of hydralazine and valproic acid in advanced previously treated solid cancers. Transl Oncol 7(3):349\u2013354","journal-title":"Transl Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2056-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-016-2056-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2056-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:42Z","timestamp":1553612862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-016-2056-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2056"],"URL":"https:\/\/doi.org\/10.1007\/s11060-016-2056-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,13]]}}}